A plasmonic nanoledge array sensor for detection of anti-insulin antibodies of type 1 diabetes biomarker
A plasmonic nanoledge array sensor for detection of anti-insulin antibodies of type 1 diabetes biomarker
复制标题
DOI：
10.1088/1361-6528/ab8c05
复制
发表时间：
2020-08-07
期刊：
影响因子：
3.5
通讯作者：
Wei, Jianjun
中科院分区：
文献类型：
--
作者：
Bagra, Bhawna;Mabe, Taylor;Wei, Jianjun
在这里，我们提出了一种具有高灵敏度和选择性的等离子体纳米边缘设备，用于简单地通过功能化设备来检测蛋白质生物标志物，该设备特异性地结合特定的生物分子或生物标志物。我们采用这种等离子体纳米边缘装置检测缓冲液和人血清中1型糖尿病（T1 D）的抗胰岛素抗体，范围为pg ml（-1）至100 ng ml（-1）。信号转导是基于通过纳米边缘阵列的异常光传输（EOT）和光谱随着表面功能化胰岛素与抗胰岛素抗体之间的生物结合反应而变化。对照实验表明，几乎没有干扰，从人血清背景和添加其他蛋白质，如牛血清白蛋白（BSA）和表皮生长因子（EGF）在20 ng ml（-1）。等离子体装置的高灵敏度、特异性和易适应性为T1 D的生物传感和诊断应用提供了新的机会。
Here we present a plasmonic nanoledge device with high sensitivity and selectivity used to detect protein biomarkers simply by functionalizing the device, which specifically binds to particular biomolecule or biomarkers. We employ this plasmonic nanoledge device for the detection of anti-insulin antibodies of type 1 diabetes (T1D) in buffer and human serum at the range of pg ml(-1) to 100 ng ml(-1). The signal transduction is based on the extraordinary optical transmission (EOT) through the nanoledge array and the optical spectral changes with the biological binding reaction between the surface functionalized insulin with anti-insulin antibody. Control experiments indicate little interferences from the human serum background and addition of other proteins such as bovine serum albumin (BSA) and epidermal growth factor (EGF) at 20 ng ml(-1). The high sensitivity, specificity and easy adaptability of the plasmonic device offer new opportunities in biosensing and diagnostic applications for T1D.